Not my profile, taken from web.


Description:
Trenbolone hexahydrobenzylcarbonate is a slow-acting
injectable ester of the potent anabolic steroid trenbolone.
Trenbolone appears most commonly as trenbolone acetate,
which is a much faster-acting form of the drug
The hexahydrobenzylcarbonate ester used here extends the
release of trenbolone for more than 2 weeks, which has
always been thought of as more suitable for human use due to
the less frequent injection schedule. The base steroid
trenbolone is roughly three times more androgenic than
testosterone, making it a fairly potent androgen. It also
displays about 3 times greater tissue-building activity in
comparison to its androgenic properties, making its official
classification as that of an anabolic steroid. The musclebuilding
effect of trenbolone is often compared to such
popular bulking agents as testosterone or Dianabol, but
without the same estrogenrelated side effects. It is most
commonly identified as a lean-mass-building drug, and is
extremely popular with athletes for its ability to promote the
rapid buildup of strength, muscle size, and definition.

History:
The first long-acting trenbolone ester (undecanoate) was
studied in 1967, described during a series of experiments
into synthetic anabolic steroids by Roussel-UCLAF.571
Trenbolone hexahydrobenzylcarbonate was a subsequent and
uniquely French slant to this long-acting anabolic steroid,
possessing an unusual but roughly equivalent compound.
Trenbolone hexahydrobenzylcarbonate was developed into a
medicine by Negma Laboratoires in France, which sold the
drug under the Parabolan trade name. It was also sold for a
period of time as Hexabolan, a name that referred to the
unusual ester it possesses. Trenbolone
hexahydrobenzylcarbonate is the only known form of
trenbolone ever produced as a medicine for human
consumption. The most notable appearance of trenbolone
comes as trenbolone acetate, which is used widely and
exclusively in veterinary medicine.
Parabolan was prescribed in France as a protein-sparing
anabolic agent in cases of cachexia (lean body mass wasting)
and malnutrition, as well as to combat certain forms of
osteoporosis. Its prescribing guidelines included
recommendations for the treatment of androgen-sensitive
populations, such as women and the elderly. Owing to its
moderate androgenic properties, however, the drug was
contraindicated in children, especially young females.
Parabolan remained on the French market for a very long
time, although it was finally discontinued (voluntarily) by
Negma in 1997. For a brief period of time it seemed that the
demise of Parabolan would mark the end of human-use
trenbolone preparations, as no other medicine approved for
human use was known to exist worldwide at the time. A very
small number of Parabolan preparations have been brought to
market since, however, so while the drug is still poorly
available, it is not completely defunct.

How Supplied:
Trenbolone hexahydrobenzylcarbonate is no longer produced
as a prescription drug product. When manufactured in France
it came in the form of a 1.5 mL ampule containing 76 mg of
steroid (product information lists this as equivalent to 50 mg
of base trenbolone).

Structural Characteristics:
Trenbolone is a modified form of nandrolone. It differs by
the introduction of double bonds at carbons 9 and 11, which
inhibit aromatization (9-ene), increase androgen-binding
affinity,572 and slows its metabolism. The resulting steroid is
significantly more potent as both an anabolic and an
androgen than its nandrolone base. The trenbolone here is
modified with a hexahydrobenzylcarbonate ester at the 17-
beta hydroxyl group, so that the free steroid is released more
slowly from the area of injection.

Side Effects (Estrogenic):
Trenbolone is not aromatized by the body, and is not
measurably estrogenic. It is of note, however, that this
steroid displays significant binding affinity for the
progesterone receptor (slightly stronger than progesterone
itself ).573 574 The side effects associated with progesterone
are similar to those of estrogen, including negative feedback
inhibition of testosterone production and enhanced rate of fat
storage. Progestins also augment the stimulatory effect of
estrogens on mammary tissue growth. There appears to be a
strong synergy between these two hormones here, such that
gynecomastia might even occur with the help of progestins
without excessive estrogen levels. The use of an antiestrogen,
which inhibits the estrogenic component of this
disorder, is often sufficient to mitigate gynecomastia caused
by progestational anabolic/androgenic steroids. Note that
progestational side effects are more common when
trenbolone is being taken with other aromatizable steroids.

Side Effects (Androgenic):
Although classified as an anabolic steroid, trenbolone is
sufficiently androgenic. Androgenic side effects are still
common with this substance, and may include bouts of oily
skin, acne, and body/facial hair growth. Anabolic/androgenic
steroids may also aggravate male pattern hair loss. Women
are also warned of the potential virilizing effects of
anabolic/androgenic steroids. These may include a
deepening of the voice, menstrual irregularities, changes in
skin texture, facial hair growth, and clitoral enlargement.
Additionally, the 5-alpha reductase enzyme does not
metabolize trenbolone575, so its relative androgenicity is not
affected by finasteride or dutasteride.

Side Effects (Hepatotoxicity):
Trenbolone is not c-17 alpha alkylated, and is generally not
considered a hepatotoxic steroid; liver toxicity is unlikely.
This steroid does have a strong level of resistance to hepatic
breakdown, however, and severe liver toxicity has been
noted in bodybuilders abusing trenbolone.576 Although
unlikely, hepatotoxicity cannot be completely excluded,
especially with high doses.

Side Effects (Cardiovascular):
Anabolic/androgenic steroids can have deleterious effects on
serum cholesterol. This includes a tendency to reduce HDL
(good) cholesterol values and increase LDL (bad)
cholesterol values, which may shift the HDL to LDL balance
in a direction that favors greater risk of arteriosclerosis. The
relative impact of an anabolic/androgenic steroid on serum
lipids is dependant on the dose, route of administration (oral
vs. injectable), type of steroid (aromatizable or nonaromatizable),
and level of resistance to hepatic metabolism.
Due to its non-aromatizable nature and strong resistance to
metabolism, trenbolone has a moderate to strong (negative)
impact on lipid values and atherogenic risk.
Anabolic/androgenic steroids may also adversely affect
blood pressure and triglycerides, reduce endothelial
relaxation, and support left ventricular hypertrophy, all
potentially increasing the risk of cardiovascular disease and
myocardial infarction.

To help reduce cardiovascular strain it is advised to
maintain an active cardiovascular exercise program and
minimize the intake of saturated fats, cholesterol, and simple
carbohydrates at all times during active AAS administration.
Supplementing with fish oils (4 grams per day) and a natural
cholesterol/antioxidant formula such as Lipid Stabil or a
product with comparable ingredients is also recommended.

Side Effects (Testosterone Suppression):
All anabolic/androgenic steroids when taken in doses
sufficient to promote muscle gain are expected to suppress
endogenous testosterone production. Without the intervention
of testosterone-stimulating substances, testosterone levels
should return to normal within 1-4 months of drug secession.
Note that prolonged hypogonadotrophic hypogonadism can
develop secondary to steroid abuse, necessitating medical
intervention. In experimental studies, trenbolone was
determined to be approximately three times stronger at
suppressing gonadotropins than testosterone on a milligram
for milligram basis.

__________________
GbnStore.Net - Why wait for tomorrow? Get Bigger Now.